Merck KGaA is a science and technology company specializing in the fields of healthcare, life science and performance materials. The company's portfolio comprises a wide array of products ranging from innovative pharmaceuticals and biopharmaceuticals to life science tools, specialty chemicals and high-tech materials.

The company is focused on oncology, multiple sclerosis, infertility, growth disorders, selected cardiovascular and metabolic diseases, women’s and children’s health, cough and cold as well as everyday health protection.

The company reports its results in three business sectors – Healthcare, Life Science and Performance Materials.

We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: The company’s fourth-quarter 2017 earnings per American Depositary Receipt (ADR) remained flat year over year at $1.54.

Revenue: The company posted revenues of $4.5 billion in the reported quarter, up 9.6% including favorable currency movement. The Healthcare and Life Science segment drove the company’s organic growth.

Key Stats: The company has proposed a dividend of €1.25, increasing the payout by €0.05 maintaining the trend of rising dividend since 2009.

2018 Guidance: For 2018, the company expects its net sales to grow moderately. The company expects currency movements to have an unfavourable impact of 4% to 6% on EBIDTA.

Merck KGaA Price and EPS Surprise

 

Merck KGaA Price and EPS Surprise | Merck KGaA Quote

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>